1 Nov Find important safety information and patient resources for all of our currently marketed medicines. Updates Package Inserts – Jan Vials Packaging Change – Aug PEGASYS® (peginterferon alfa-2a), as part of a combination regimen with other. 11 Mar PEGASYS: Peginterferon alfa-2a is a covalent conjugate of recombinant leukocyte interferon gene inserted into and expressed in E. coli.

Author: Kimi Tugor
Country: Malawi
Language: English (Spanish)
Genre: Life
Published (Last): 10 January 2009
Pages: 37
PDF File Size: 8.44 Mb
ePub File Size: 19.78 Mb
ISBN: 424-2-55872-648-1
Downloads: 12164
Price: Free* [*Free Regsitration Required]
Uploader: Vubei

Do not touch the cleaned rubber stopper. The peak to trough ratio at week 48 is onsert 2. This is a safety device. Median platelet counts return to pre-treatment levels 4 weeks after the pegasys package insert of therapy.

Symptoms of thyroid changes include feeling cold or hot all the time, a change in your weight, and pegasys package insert to your skin, trouble concentrating. Get medical help right away if you get any of the following symptoms: If no blood is present in the syringe, inject the medicine by gently pressing the plunger all the way down the syringe barrel, until the syringe is pegasys package insert.

Your healthcare provider may want to examine you and do blood tests.

Find a well-lit, clean, flat surface such as a table. Additional testing pegasys package insert oackage performed pegaasys during therapy. A return to normal menstrual rhythm followed cessation of treatment. You will need the following supplies: Refer to the prescribing information of the other HCV antiviral drugs, including ribavirin, for a list of their contraindications. Pediatric Pegasys package insert Decreases in hemoglobin, neutrophils and platelets may require dose reduction or permanent discontinuation from treatment in pediatric subjects [see Dosage and Administration 2.

Most Related  2N3019 DOWNLOAD

Genentech: Pegasys® (peginterferon alfa-2a) – Information for Patients

All subjects received 48 weeks of therapy followed by 24 weeks of treatment-free follow-up. In adult patients with persistent, severe ALT greater pegasys package insert 10 times above the upper limit of normal hepatitis B flares, consideration should be given to discontinuation of treatment.

See ” How should I pegasys package insert of used syringes, needles, and vials? Each needle has a needle-stick protection device. Events occurred in patients with few or no reported risk factors for stroke, including patients less than 45 years of age. All subjects were adults, had compensated liver disease, detectable hepatitis Pegasys package insert virus HCVliver biopsy diagnosis of chronic hepatitis, and were previously untreated with interferon.

Do not warm up the autoinjector in any other way. Lay the syringe on a flat clean surface and wait inesrt few minutes until it reaches room temperature.

Patient Resources

Serious liver problems, worsening of liver problems including liver failure and death. Patients experiencing ALT flares should receive more frequent monitoring of liver function.


Call your healthcare provider if you have any of these symptoms. How should I give an injection?

Never reuse disposable prefilled syringes and needles. Position the point of the needle the bevel so it is facing up see Figure K.

The mean terminal half-life after subcutaneous dosing in subjects pegwsys chronic hepatitis Pegassy was hours range 84 to hours compared to 5 hours range pegasys package insert.

Refer to the prescribing information of ribavirin for the recommended dosage and duration. Figure “B” Look at the autoinjector to make sure that it is not damaged in any way. Using your thumb and finger, tap the syringe to bring pegasys package insert bubbles to the top see Figure J. Continue reduced dosage or return to normal dosage.

You pegasys package insert also report side effects to Genentech at The dose may be reduced to 90 mcg once weekly as appropriate [see Dosage and Administration 2. Patients should be advised to report any sign or symptom of depression or suicidal ideation to their prescribing physicians.